SEFC

Spectrally encoded flow cytometry

Coordinatore	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Israel [IL]
Totale costo	163˙680 €
EC contributo	149˙848 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-07-01   -   2013-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY  Organization address address: TECHNION CITY - SENATE BUILDING city: HAIFA postcode: 32000 contact info Titolo: Mr. Nome: Mark Cognome: Davison Email: send email Telefono: +972 4 829 3097 Fax: +972 4 823 2958	IL (HAIFA)	hostInstitution	149˙848.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Measuring blood parameters noninvasively in patients is of great importance in many clinical applications. During the course of our research in an ERC-funded project, in which light is used to image and threat cancer, we have discovered that the minimally invasive imaging technique we have been developing, termed spectrally encoded endoscopy, is extremely effective for imaging flowing blood cells without the need for mechanical scanning. We have shown that this technique, termed spectrally encoded flow cytometry (SEFC), is capable of subsurface confocal imaging at sub-micron resolutions, at speeds that are sufficient for the detection of rapid capillary flow. Being able to image microscopic cellular features in patients without pain, stress, timely analysis and risk of infection, this technique represents an uncharted territory in medical diagnosis, and would have a wide variety of applications in routine care, intensive care and in the operating room. During the twelve months of the requested fund, we plan to complete a system prototype for future pre-clinical and clinical tests and establish a feasible business plan for further commercialization of the technology.'